Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ANI Pharmaceuticals, Inc. (Nasdaq: ANIP), a diversified biopharmaceutical company focused on rare disease, generics, and branded therapeutics. Through these filings, investors can review how ANI reports its financial results, capital structure changes, and other material events related to its Rare Disease, Generics, and Brands businesses.
ANI frequently files Form 8-K current reports to disclose quarterly and year-to-date financial results, updated investor presentations, and other significant developments. For example, recent 8-K filings reference press releases announcing results for specific quarters, updated guidance, and the publication of investor presentations that describe the company’s strategy, segment performance, and focus on products such as Purified Cortrophin Gel and ILUVIEN. Other 8-K filings discuss matters like the conversion of Series A Convertible Preferred Stock into common shares and updates on litigation outcomes.
In addition to 8-Ks, investors can use this filings page to locate ANI’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide more detailed discussions of segment results, risk factors, product portfolios, and the company’s rare disease strategy. These periodic reports elaborate on how ANI’s Rare Disease, Generics, and Brands businesses contribute to overall performance and outline risks related to manufacturing, regulatory approvals, competition, and market conditions.
Filings related to equity and capital structure are also important for ANIP. For instance, the company has reported on the issuance and subsequent conversion of Series A Convertible Preferred Stock, including dividend terms and conversion conditions, and on the issuance of common shares upon conversion under exemptions from registration. Such disclosures help investors understand changes in outstanding securities and potential dilution.
Stock Titan enhances this information by offering AI-powered summaries of ANI’s key filings. These summaries highlight the main points from lengthy documents, such as revenue trends, segment performance, major product updates, and notable legal or corporate events. Users can quickly scan 10-Ks, 10-Qs, and 8-Ks, and then dive into the full text on EDGAR for deeper analysis. The filings page also surfaces information relevant to insider and security-holder activity where reported, enabling a more complete view of ANI Pharmaceuticals’ regulatory and financial disclosures.
ANI Pharmaceuticals senior vice president of generics, Ori Gutwerg, reported two equity-related transactions in common stock. On February 26, 2026, he acquired 12,969 shares at $77.15 per share as a grant or award, bringing his direct holdings to 89,063 shares. According to a footnote, this restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.
On February 28, 2026, 2,221 shares were disposed of at $73.90 per share in a tax-withholding disposition related to the vesting of 4,342 previously granted restricted shares, leaving Gutwerg with 86,842 directly owned shares.
ANI Pharmaceuticals SVP Chad Gassert reported equity compensation and related tax withholding transactions in company stock. On February 26, 2026, he acquired 11,116 shares of common stock as a restricted stock award at $77.15 per share, scheduled to vest in four equal annual installments on the first through fourth anniversaries of February 26, 2026.
On February 28, 2026, 2,221 shares were withheld at $73.90 per share to cover taxes tied to the vesting of 4,342 previously granted restricted shares, leaving 74,916 shares held directly. He also has indirect ownership of 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.
ANI Pharmaceuticals senior vice president and chief HR officer Krista Davis reported two stock transactions involving company common shares. On February 26, 2026, she acquired 10,810 shares through a restricted stock award at $77.15 per share, bringing her direct holdings to 60,073 shares. This award is scheduled to vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026. On February 28, 2026, 1,555 shares were withheld at $73.90 per share to cover tax obligations related to the vesting of a prior restricted stock grant, leaving her with 58,518 directly owned shares. The tax withholding is characterized as a payment of tax liability by delivering securities, not an open-market sale.
ANI Pharmaceuticals senior vice president and general counsel Meredith Cook reported equity compensation activity in company stock. On February 26, 2026, Cook acquired 13,895 shares of common stock as a restricted stock award at $77.15 per share, which will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. On February 28, 2026, 1,555 shares at $73.90 per share were disposed of through shares withheld for tax purposes in connection with the vesting of 3,040 previously granted restricted shares. After these transactions, Cook directly owned 79,890 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported two equity transactions in company common stock. On February 26, 2026, he received a grant of 22,233 restricted shares at $77.15 per share, which will vest in four equal annual installments starting on the first anniversary of that date. On February 28, 2026, 2,773 shares at $73.90 per share were disposed of for tax withholding in connection with the vesting of 6,079 previously granted restricted shares. After these transactions, he directly owned 189,543 common shares.
ANI Pharmaceuticals files its annual report describing a diversified biopharma business built around Rare Disease, Generics, and Brands. The company highlights the September 2024 acquisition of Alimera Sciences, adding the retina drugs ILUVIEN and YUTIQ and expanding its international footprint.
In 2025, the FDA approved an expanded U.S. label for ILUVIEN to treat both diabetic macular edema and chronic non‑infectious uveitis, and cleared a prefilled syringe format for Cortrophin Gel to simplify use. ANI also strengthened its capital structure with a $325.0 million term loan, a $75.0 million revolver, and $316.25 million of convertible notes due 2029, largely used to fund the Alimera deal and refinance prior debt.
The Generics portfolio exceeds 120 products, and management targets 10–15 new launches per year while emphasizing niche, lower‑competition areas. As of June 30, 2025, non‑affiliate equity market value was about $1.3 billion, and as of February 20, 2026, there were 22,414,104 common shares outstanding.
ANI Pharmaceuticals reported record fourth quarter and full-year 2025 results and reaffirmed its 2026 financial guidance. Full-year net revenues reached $883.4 million, up 43.8%, with Q4 revenues of $247.1 million, up 29.6% from 2024.
Rare Disease revenue grew strongly to $422.6 million in 2025, led by Cortrophin Gel at $347.8 million, up 75.6%. GAAP net income available to common shareholders was $77.2 million versus a prior-year loss, and adjusted non-GAAP EBITDA rose to $229.8 million, up 47.3%. 2026 guidance calls for total revenue of $1.055–$1.115 billion and adjusted diluted EPS of $8.83–$9.34. The company ended 2025 with $285.6 million in cash and $629.1 million in principal debt.
ANI Pharmaceuticals executive Christopher Mutz reported an open-market sale of company stock. On the reported date, he sold 5,323 shares of ANI Pharmaceuticals common stock at a weighted average price of $78.02 per share, with individual trade prices ranging from $77.20 to $78.58.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. After this sale, Mutz directly holds 84,840 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals senior vice president and chief human resources officer Krista Davis sold a total of 3,814 shares of Common Stock in open‑market transactions. She sold 2,084 shares at a weighted average price of $77.53 on February 19, 2026 and 1,730 shares at $77.99 on February 20, 2026. The sales were executed under a Rule 10b5‑1 trading plan adopted on September 18, 2025, and she held 49,263 shares directly after the most recent sale.
Rowland Thomas Andrew reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 1,051 shares at a weighted average price of $77.00 per share. Following the reported transactions, holdings were 38,109 shares.